FDA updates Gilead’s label for CAR-T Tecartus with new boxed warning for secondary cancer

The FDA on Monday pulled but then updated and published a new letter to Gilead advising that its CAR-T drug Tecartus does need a boxed warning for secondary cancer, reaffirming that this is a class-wide risk in the eyes of the regulatory agency.

Last week, the FDA…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks